JPS643128A - Bifunctional antibody structure and selective breakage of cell population - Google Patents
Bifunctional antibody structure and selective breakage of cell populationInfo
- Publication number
- JPS643128A JPS643128A JP63137599A JP13759988A JPS643128A JP S643128 A JPS643128 A JP S643128A JP 63137599 A JP63137599 A JP 63137599A JP 13759988 A JP13759988 A JP 13759988A JP S643128 A JPS643128 A JP S643128A
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- specific
- target cell
- bound
- antibody structure
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6879—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the immunoglobulin having two or more different antigen-binding sites, e.g. bispecific or multispecific immunoglobulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6020587A | 1987-06-10 | 1987-06-10 | |
| US060205 | 1987-06-10 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH013128A JPH013128A (ja) | 1989-01-06 |
| JPS643128A true JPS643128A (en) | 1989-01-06 |
Family
ID=22028021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP63137599A Pending JPS643128A (en) | 1987-06-10 | 1988-06-06 | Bifunctional antibody structure and selective breakage of cell population |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP0294703B1 (ja) |
| JP (1) | JPS643128A (ja) |
| AT (1) | ATE122238T1 (ja) |
| DE (1) | DE3853740T2 (ja) |
| ES (1) | ES2073394T3 (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005518431A (ja) * | 2002-02-01 | 2005-06-23 | アボット・ラボラトリーズ | 高分子コンジュゲート及びその製造方法 |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6121424A (en) | 1991-11-25 | 2000-09-19 | Enzon, Inc. | Multivalent antigen-binding proteins |
| US5869620A (en) * | 1986-09-02 | 1999-02-09 | Enzon, Inc. | Multivalent antigen-binding proteins |
| WO1989006544A1 (en) * | 1988-01-15 | 1989-07-27 | Centocor, Inc. | Heteroligating antibodies and therapeutic uses thereof |
| US4925648A (en) * | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
| US5173293A (en) * | 1989-02-23 | 1992-12-22 | Becton Dickinson And Company | Anti-T-cell antibodies as adjuvants |
| US5225538A (en) * | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5116964A (en) * | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US6406697B1 (en) | 1989-02-23 | 2002-06-18 | Genentech, Inc. | Hybrid immunoglobulins |
| FR2649119A1 (fr) * | 1989-06-30 | 1991-01-04 | Centre Nat Rech Scient | Procede de pilotage de retrovirus en utilisant des complexes bifonctionnels |
| AU6290090A (en) * | 1989-08-29 | 1991-04-08 | University Of Southampton | Bi-or trispecific (fab)3 or (fab)4 conjugates |
| US5650150A (en) * | 1990-11-09 | 1997-07-22 | Gillies; Stephen D. | Recombinant antibody cytokine fusion proteins |
| AU5670194A (en) * | 1992-11-20 | 1994-06-22 | Enzon, Inc. | Linker for linked fusion polypeptides |
| UA40577C2 (uk) * | 1993-08-02 | 2001-08-15 | Мерк Патент Гмбх | Біспецифічна молекула, що використовується для лізису пухлинних клітин, спосіб її одержання, моноклональне антитіло (варіанти), фармацевтичний препарат, фармацевтичний набір (варіанти), спосіб видалення пухлинних клітин |
| US5723125A (en) * | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
| ES2221717T3 (es) | 1997-12-08 | 2005-01-01 | Emd Lexigen Research Center Corp. | Proteinas de fusion heterodimeras utiles para inmunoterapia dirigida e inmunoestimulacion general. |
| US7067110B1 (en) | 1999-07-21 | 2006-06-27 | Emd Lexigen Research Center Corp. | Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| SK782002A3 (en) | 1999-07-21 | 2003-08-05 | Lexigen Pharm Corp | FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens |
| US6617135B1 (en) | 1999-08-09 | 2003-09-09 | Emd Lexigen Research Center Corp. | Multiple cytokine protein complexes |
| CA2391080A1 (en) | 1999-11-12 | 2001-05-25 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Erythropoietin forms with improved properties |
| DK1252192T3 (da) | 2000-02-11 | 2006-11-20 | Merck Patent Gmbh | Forbedring af antistofbaserede fusionsproteiners serumhalveringstid |
| RU2272644C2 (ru) | 2000-06-29 | 2006-03-27 | Мерк Патент Гмбх | Усиление иммунной реакции, медиатором которой является слитый протеин антитело-цитокин, при помощи комбинированного лечения агентами, увеличивающими поглощение иммуноцитокина |
| KR100900176B1 (ko) | 2001-03-07 | 2009-06-02 | 메르크 파텐트 게엠베하 | 하이브리드 이소타입 항체 부분구조를 포함하는 단백질을위한 발현 기술 |
| US6992174B2 (en) | 2001-03-30 | 2006-01-31 | Emd Lexigen Research Center Corp. | Reducing the immunogenicity of fusion proteins |
| CA2446087C (en) | 2001-05-03 | 2013-06-18 | Stephen D. Gillies | Recombinant tumor specific antibody and use thereof |
| BR0214650A (pt) | 2001-12-04 | 2005-05-03 | Merck Patent Gmbh | Imunocitoquinas com seletividade modulada |
| EP1622645B1 (en) * | 2002-04-23 | 2013-10-23 | Roger Williams Hospital | Compositions and methods for stem cell delivery |
| WO2004041862A2 (en) | 2002-11-08 | 2004-05-21 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| EP1558647B1 (en) | 2002-11-08 | 2015-06-10 | Ablynx N.V. | Single domain antibodies directed against tumour necrosis factor-alpha and uses therefor |
| JP4494977B2 (ja) | 2002-12-17 | 2010-06-30 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｇｄ２に結合するマウス１４．１８抗体のヒト化抗体（ｈ１４．１８）およびそのｉｌ−２融合タンパク質 |
| RU2357974C2 (ru) | 2003-01-10 | 2009-06-10 | Аблинкс Н.В. | Терапевтические полипептиды, их гомологи, их фрагменты и их применение для модуляции агрегации, опосредованной тромбоцитами |
| ATE485307T1 (de) | 2003-11-07 | 2010-11-15 | Ablynx Nv | Camelidae schwere ketten antikörper vhhs gegen epidermalen wachstumfaktor rezeptor (egfr) und ihre verwendung |
| DK1699822T3 (da) | 2003-12-30 | 2008-08-04 | Merck Patent Gmbh | IL-7-fusionsproteiner med antistofdele, fremstilling deraf og anvendelse deraf |
| WO2005063808A1 (en) | 2003-12-31 | 2005-07-14 | Merck Patent Gmbh | Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS |
| ATE443724T1 (de) | 2004-01-22 | 2009-10-15 | Merck Patent Gmbh | Antikrebs-antikörper mit reduzierter komplementfixierung |
| US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| ATE465176T1 (de) | 2004-12-09 | 2010-05-15 | Merck Patent Gmbh | Il-7-varianten mit reduzierter immunogenität |
| RU2464276C2 (ru) | 2005-05-18 | 2012-10-20 | Аблинкс Н.В. | Улучшенные нанотела против фактора некроза опухоли-альфа |
| DK2444424T3 (en) | 2005-05-20 | 2018-12-03 | Ablynx Nv | IMPROVED NANOL BODIES (TM) FOR TREATING AGGREGATED MEDICINAL DISORDERS |
| CA2635623C (en) | 2005-12-30 | 2015-02-17 | Michael Super | Anti-cd19 antibodies with reduced immunogenicity |
| ES2384055T3 (es) | 2005-12-30 | 2012-06-28 | Merck Patent Gmbh | Variantes de la interleucina-12p40 con estabilidad mejorada |
| CA2759333A1 (en) | 2009-04-22 | 2010-10-28 | Merck Patent Gmbh | Antibody fusion proteins with modified fcrn binding sites |
| EP2491056B1 (en) | 2009-10-22 | 2021-09-15 | Universiteit Twente | Vhh for application in tissue repair, organ regeneration, organ replacement and tissue engineering |
| DK3411398T3 (da) | 2016-02-05 | 2024-06-24 | Orionis Biosciences BV | Målrettede terapeutiske midler og anvendelse heraf |
| JP7657014B2 (ja) | 2016-03-07 | 2025-04-04 | ブイアイビー ブイゼットダブリュー | Ｃｄ２０結合単一ドメイン抗体 |
| EP3455245A2 (en) | 2016-05-13 | 2019-03-20 | Orionis Biosciences NV | Therapeutic targeting of non-cellular structures |
| CA3052523A1 (en) | 2017-02-06 | 2018-08-09 | Orionis Biosciences Nv | Targeted chimeric proteins and uses thereof |
| US20200354424A1 (en) | 2018-01-26 | 2020-11-12 | Orionis Biosciences, Inc. | Xcr1 binding agents and uses thereof |
| AU2019215440B2 (en) | 2018-02-05 | 2025-12-04 | Orionis Biosciences, Inc. | Fibroblast binding agents and use thereof |
| TWI905099B (zh) | 2019-05-21 | 2025-11-21 | 瑞士商諾華公司 | Cd19 結合分子及其用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8626412D0 (en) * | 1986-11-05 | 1986-12-03 | Clark M R | Antibodies |
| US4882424A (en) * | 1987-05-11 | 1989-11-21 | Dana-Farber Cancer Institute, Inc. | Activation antigen |
-
1988
- 1988-06-01 ES ES88108793T patent/ES2073394T3/es not_active Expired - Lifetime
- 1988-06-01 EP EP88108793A patent/EP0294703B1/en not_active Expired - Lifetime
- 1988-06-01 AT AT88108793T patent/ATE122238T1/de not_active IP Right Cessation
- 1988-06-01 DE DE3853740T patent/DE3853740T2/de not_active Expired - Fee Related
- 1988-06-06 JP JP63137599A patent/JPS643128A/ja active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005518431A (ja) * | 2002-02-01 | 2005-06-23 | アボット・ラボラトリーズ | 高分子コンジュゲート及びその製造方法 |
| JP2009294216A (ja) * | 2002-02-01 | 2009-12-17 | Abbott Lab | 高分子コンジュゲート及びその製造方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0294703A2 (en) | 1988-12-14 |
| ATE122238T1 (de) | 1995-05-15 |
| ES2073394T3 (es) | 1995-08-16 |
| EP0294703A3 (en) | 1990-06-27 |
| EP0294703B1 (en) | 1995-05-10 |
| DE3853740T2 (de) | 1995-11-09 |
| DE3853740D1 (de) | 1995-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS643128A (en) | Bifunctional antibody structure and selective breakage of cell population | |
| EP0096375A3 (en) | Device for separating serum from blood sample | |
| AU1898988A (en) | Flow injection apparatus for carrying out chemical analyses | |
| DK0412486T3 (da) | Antistoffer mod TNF-bindingsprotein I og F(ab)-fragmenter | |
| AU2543777A (en) | Specific binding assay method'and reagent means | |
| FR2618855B1 (fr) | Dispositif de recuperation de vapeurs d'essence | |
| GB2121170B (en) | Method for eliminating glucose dependent schiff base effect from hemoglobin a1 assay | |
| NZ217339A (en) | Immunoassay for progesterone using monoclonal antibodies | |
| IL62267A0 (en) | Labeled antibodies,compositions containing them and methods for the use thereof | |
| DK234785A (da) | Immunanalyse for serumantistoffer | |
| AU7473087A (en) | Apparatus for immunoassay with antibody or antigen attached to walls | |
| EP0149684A4 (en) | ELECTRODE STRUCTURE FOR RECORDING DEVICE. | |
| KR880700814A (ko) | 아미노글리코사이드 스테로이드, 이의 제조방법, 이의 용도 및 이를 함유하는 약제학적 조성물 | |
| DK109887D0 (da) | Farmaceutisk praeparat indeholdende antistoffer | |
| EP0109434A4 (en) | IN VITRO DIAGNOSTICS METHODS USING MONOCLONAL ANTIBODIES AGAINST PROTEINS OF CONNECTIVE TISSUES. | |
| AU2420888A (en) | Immunoassay for antibodies binding platelets | |
| OA07341A (fr) | Nouveaux oximéthers, procédé pour leur préparation, agents contenant les nouveaux oximéthers et leur application. | |
| KR880700815A (ko) | 아미노글리코사이드 스테로이드, 그의 제조방법, 그의 용도 및 이를 함유하는 약제학적 조성물 | |
| AU8944291A (en) | Immunoassay for the determination of anti-hiv antibodies in human samples | |
| IL77990A (en) | Monoclonal anti-alpha-amylase antibody,process for obtaining the same and pharmaceutical compositions containing the same | |
| DK160779C (da) | Indretning, der navnlig er anvendelig til pyrolyse af faste eller vaeskeformige proever, der er udtaget i lille maengde | |
| IT209873Z2 (it) | Dispositivo circuitale per il rilevamento dell'assetto di veicoli. | |
| FR2634063B1 (fr) | Interface microsonde laser pour spectrometre de masse | |
| IL86710A0 (en) | Polypeptide receptor for interleukin-2,antibodies against this polypeptide and pharmaceutical compositions containing the same | |
| DK555683D0 (da) | Dinucleosider af typen 3',5'-arabinosider, fremgangsmade til fremstilling af sadanne dinucleosider og laegemiddel indeholdende disse |